Effects of roniciclib in preclinical models of anaplastic thyroid cancer

Shu-Fu Lin; Jen-Der Lin; Chuen Hsueh; Ting-Chao Chou; Richard J. Wong

doi:10.18632/oncotarget.19092

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Effects of roniciclib in preclinical models of anaplastic thyroid cancer

Shu-Fu Lin _, Jen-Der Lin, Chuen Hsueh, Ting-Chao Chou and Richard J. Wong

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:67990-68000. https://doi.org/10.18632/oncotarget.19092

Metrics: PDF 1289 views | HTML 2159 views | ?

Abstract

Shu-Fu Lin1, Jen-Der Lin1, Chuen Hsueh2, Ting-Chao Chou3,4 and Richard J. Wong5

1Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan

2Department of Pathology, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan

3Laboratory of Preclinical Pharmacology Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA

4Current address: PD Science, Inc., Paramus, NJ, USA

5Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Correspondence to:

Shu-Fu Lin, email: [email protected]

Keywords: roniciclib, cyclin-dependent kinase, anaplastic thyroid cancer

Received: March 02, 2017 Accepted: May 23, 2017 Published: July 08, 2017

ABSTRACT

Many human cancers have altered cyclin-dependent kinase activity. Inhibition of cyclin-dependent kinases may arrest cell cycle progression and represents an important strategy in the treatment of malignancies. We evaluated the therapeutic effects of roniciclib, a cyclin-dependent kinase inhibitor, as a treatment for anaplastic thyroid cancer. Roniciclib inhibited anaplastic thyroid cancer cell proliferation in a dose-dependent manner. Roniciclib activated caspase-3 activity and induced apoptosis. Cell cycle progression was arrested in G2/M phase. In vivo, the growth of anaplastic thyroid cancer xenograft tumors was retarded by roniciclib treatment without evidence of toxicity. These data provide a rationale for further clinical evaluation using roniciclib in the treatment of patients with anaplastic thyroid cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19092

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Effects of roniciclib in preclinical models of anaplastic thyroid cancer

Abstract